Well, if Generex is cleaning up things, I can understand events taking a bit slower, concerning documents clearing, etc. with the SEC and even being put in.
Buildit did bring up a good point, and correct me if I am wrong in what you said Buildit, but does Generex need to get a new S-1 approved for GNBT now or can NGIO S-1 be submitted now, based on what Doc said?
There is so much going on right now, that I think this is the underlying problem with everything and this is why it gets so frustrating when you see the PPS down so low and not hearing any substantial news. When you have the deals taking place, you have the testing, then all the documents being put into the SEC, what needs to be approved, what doesn't, it's like going through a minefield trying to figure everything out.
There are a lot of balls juggling in the air right now for Generex / NGIO and we are all trying to watch them all wondering if any are going to drop or stay juggling successfully.
I really want Generex / NGIO to succeed, for everyone. Lord knows I have a substantial investment in them and I have no plans yet to sell it. I still think the potential is way up there and when you read what Ari wrote, it just reinforces that view, not just with a Covid vaccine, but with a whole product line. They just need one real break, just one and it's off to the races for them. Just one real break.
Buildit did bring up a good point, and correct me if I am wrong in what you said Buildit, but does Generex need to get a new S-1 approved for GNBT now or can NGIO S-1 be submitted now, based on what Doc said?
There is so much going on right now, that I think this is the underlying problem with everything and this is why it gets so frustrating when you see the PPS down so low and not hearing any substantial news. When you have the deals taking place, you have the testing, then all the documents being put into the SEC, what needs to be approved, what doesn't, it's like going through a minefield trying to figure everything out.
There are a lot of balls juggling in the air right now for Generex / NGIO and we are all trying to watch them all wondering if any are going to drop or stay juggling successfully.
I really want Generex / NGIO to succeed, for everyone. Lord knows I have a substantial investment in them and I have no plans yet to sell it. I still think the potential is way up there and when you read what Ari wrote, it just reinforces that view, not just with a Covid vaccine, but with a whole product line. They just need one real break, just one and it's off to the races for them. Just one real break.
1
